112 related articles for article (PubMed ID: 18538832)
21. p14 expression differences in ovarian benign, borderline and malignant epithelial tumors.
Cabral VD; Cerski MR; Sa Brito IT; Kliemann LM
J Ovarian Res; 2016 Oct; 9(1):69. PubMed ID: 27770808
[TBL] [Abstract][Full Text] [Related]
22. Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia.
Shibata K; Kajiyama H; Mizokami Y; Ino K; Nomura S; Mizutani S; Terauchi M; Kikkawa F
Gynecol Oncol; 2005 Jul; 98(1):11-8. PubMed ID: 15907336
[TBL] [Abstract][Full Text] [Related]
23. Overexpression of SOX2 is involved in paclitaxel resistance of ovarian cancer via the PI3K/Akt pathway.
Li Y; Chen K; Li L; Li R; Zhang J; Ren W
Tumour Biol; 2015 Dec; 36(12):9823-8. PubMed ID: 26159849
[TBL] [Abstract][Full Text] [Related]
24. Sperm associated antigen 9 (SPAG9) a promising therapeutic target of ovarian carcinoma.
Jagadish N; Fatima R; Sharma A; Devi S; Suri V; Kumar V; Suri A
Tumour Biol; 2018 May; 40(5):1010428318773652. PubMed ID: 29745297
[TBL] [Abstract][Full Text] [Related]
25. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
[TBL] [Abstract][Full Text] [Related]
26. Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival.
Behbakht K; Qamar L; Aldridge CS; Coletta RD; Davidson SA; Thorburn A; Ford HL
Cancer Res; 2007 Apr; 67(7):3036-42. PubMed ID: 17409410
[TBL] [Abstract][Full Text] [Related]
27. Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability.
Yang H; Mao W; Rodriguez-Aguayo C; Mangala LS; Bartholomeusz G; Iles LR; Jennings NB; Ahmed AA; Sood AK; Lopez-Berestein G; Lu Z; Bast RC
Clin Cancer Res; 2018 Oct; 24(20):5072-5084. PubMed ID: 30084832
[No Abstract] [Full Text] [Related]
28. Loss of ITM2A, a novel tumor suppressor of ovarian cancer through G2/M cell cycle arrest, is a poor prognostic factor of epithelial ovarian cancer.
Nguyen TM; Shin IW; Lee TJ; Park J; Kim JH; Park MS; Lee EJ
Gynecol Oncol; 2016 Mar; 140(3):545-53. PubMed ID: 26691219
[TBL] [Abstract][Full Text] [Related]
29. Musashi-2 is a novel regulator of paclitaxel sensitivity in ovarian cancer cells.
Lee J; An S; Choi YM; Lee J; Ahn KJ; Lee JH; Kim TJ; An IS; Bae S
Int J Oncol; 2016 Nov; 49(5):1945-1952. PubMed ID: 27600258
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of tissue protein expression levels of MIB-1 (Ki-67) in Danish ovarian cancer patients. From the 'MALOVA' ovarian cancer study.
Heeran MC; Høgdall CK; Kjaer SK; Christensen L; Jensen A; Blaakaer J; Christensen IJ; Høgdall EV
APMIS; 2013 Dec; 121(12):1177-86. PubMed ID: 23594232
[TBL] [Abstract][Full Text] [Related]
31. Defective expression of Protein 4.1N is correlated to tumor progression, aggressive behaviors and chemotherapy resistance in epithelial ovarian cancer.
Xi C; Ren C; Hu A; Lin J; Yao Q; Wang Y; Gao Z; An X; Liu C
Gynecol Oncol; 2013 Dec; 131(3):764-71. PubMed ID: 23994105
[TBL] [Abstract][Full Text] [Related]
32. RhoC is a major target of microRNA-93-5P in epithelial ovarian carcinoma tumorigenesis and progression.
Chen X; Chen S; Xiu YL; Sun KX; Zong ZH; Zhao Y
Mol Cancer; 2015 Feb; 14(1):31. PubMed ID: 25649143
[TBL] [Abstract][Full Text] [Related]
33. Ovarian carcinomas: CCN genes are aberrantly expressed and CCN1 promotes proliferation of these cells.
Gery S; Xie D; Yin D; Gabra H; Miller C; Wang H; Scott D; Yi WS; Popoviciu ML; Said JW; Koeffler HP
Clin Cancer Res; 2005 Oct; 11(20):7243-54. PubMed ID: 16243794
[TBL] [Abstract][Full Text] [Related]
34. [Reverse of the resistance to paclitaxel of the heparin binding-epidermal growth factor-like growth factor inhibitor in ovarian cancer].
Tang XH; Lu MS; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2017 Feb; 52(2):110-115. PubMed ID: 28253574
[No Abstract] [Full Text] [Related]
35. Overexpression of astrocyte-elevated gene-1 is associated with ovarian cancer development and progression.
Zhou B; Yang J; Shu B; Liu K; Xue L; Su N; Liu J; Xi T
Mol Med Rep; 2015 Apr; 11(4):2981-90. PubMed ID: 25483832
[TBL] [Abstract][Full Text] [Related]
36. Expression of p57kip2 and its clinical relevance in epithelial ovarian tumors.
Sui L; Dong Y; Ohno M; Watanabe Y; Sugimoto K; Tokuda M
Anticancer Res; 2002; 22(6A):3191-6. PubMed ID: 12530064
[TBL] [Abstract][Full Text] [Related]
37. Alteration and clinical relevance of PTEN expression and its correlation with survivin expression in epithelial ovarian tumors.
Sui L; Dong Y; Watanabe Y; Yamaguchi F; Sugimoto K; Tokuda M
Oncol Rep; 2006 Apr; 15(4):773-8. PubMed ID: 16525657
[TBL] [Abstract][Full Text] [Related]
38. [Expression of survivin gene and its relation with the expression of bcl-2 and bax protein in epithelial ovarian cancer].
Zhang SL; Zhao CQ; Lin B; Li Y; Gao H
Zhonghua Fu Chan Ke Za Zhi; 2003 Apr; 38(4):203-6. PubMed ID: 12885364
[TBL] [Abstract][Full Text] [Related]
39. Highly expressed NRSN2 is related to malignant phenotype in ovarian cancer.
Tang W; Ren A; Xiao H; Sun H; Li B
Biomed Pharmacother; 2017 Jan; 85():248-255. PubMed ID: 27908706
[TBL] [Abstract][Full Text] [Related]
40. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
